Celldex Therapeutics IncNASDAQ:CLDX
- LAST PRICE40.2700
- TODAY'S CHANGE (%)0.3500 (0.8768%)
- Bid / Lots40.2300/ 4
- Ask / Lots40.3100/ 1
- Open / Previous Close40.3800 / 39.9200
- Day Range
- 52 Week Range
- Volume65,413
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CLDX |
|---|---|---|
| 09:32 ET | 2020 | 40.38 |
| 09:34 ET | 200 | 40.76 |
| 09:36 ET | 2001 | 40.445 |
| 09:38 ET | 614 | 40.6399 |
| 09:41 ET | 100 | 40.34 |
| 09:43 ET | 100 | 40.31 |
| 09:48 ET | 102 | 40.37 |
| 09:50 ET | 508 | 40.295 |
| 09:52 ET | 1244 | 40.41 |
| 09:54 ET | 1606 | 40.285 |
| 09:56 ET | 7669 | 40.19 |
| 09:57 ET | 4086 | 40.46 |
| 09:59 ET | 1000 | 40.63 |
| 10:01 ET | 2599 | 40.54 |
| 10:03 ET | 300 | 40.58 |
| 10:06 ET | 566 | 40.745 |
| 10:08 ET | 200 | 40.81 |
| 10:10 ET | 100 | 40.74 |
| 10:12 ET | 900 | 40.69 |
| 10:19 ET | 100 | 40.72 |
| 10:21 ET | 890 | 40.53 |
| 10:24 ET | 100 | 40.58 |
| 10:26 ET | 300 | 40.59 |
| 10:30 ET | 100 | 40.64 |
| 10:32 ET | 200 | 40.555 |
| 10:33 ET | 100 | 40.605 |
| 10:37 ET | 300 | 40.53 |
| 10:42 ET | 500 | 40.44 |
| 10:44 ET | 600 | 40.47 |
| 10:46 ET | 653 | 40.49 |
| 10:48 ET | 100 | 40.49 |
| 10:50 ET | 500 | 40.585 |
| 10:51 ET | 900 | 40.45 |
| 10:53 ET | 200 | 40.435 |
| 10:55 ET | 200 | 40.43 |
| 10:57 ET | 100 | 40.42 |
| 11:00 ET | 400 | 40.425 |
| 11:02 ET | 100 | 40.455 |
| 11:04 ET | 100 | 40.445 |
| 11:08 ET | 750 | 40.505 |
| 11:09 ET | 100 | 40.505 |
| 11:11 ET | 300 | 40.51 |
| 11:13 ET | 500 | 40.46 |
| 11:15 ET | 100 | 40.45 |
| 11:18 ET | 400 | 40.515 |
| 11:20 ET | 100 | 40.525 |
| 11:22 ET | 100 | 40.52 |
| 11:24 ET | 200 | 40.52 |
| 11:27 ET | 400 | 40.44 |
| 11:29 ET | 100 | 40.285 |
| 11:31 ET | 100 | 40.18 |
| 11:36 ET | 600 | 40.23 |
| 11:38 ET | 128 | 40.29 |
| 11:44 ET | 100 | 40.14 |
| 11:47 ET | 200 | 40.19 |
| 11:49 ET | 100 | 40.24 |
| 11:51 ET | 100 | 40.17 |
| 11:54 ET | 200 | 40.15 |
| 11:56 ET | 300 | 40.22 |
| 11:58 ET | 100 | 40.235 |
| 12:00 ET | 500 | 40.17 |
| 12:07 ET | 100 | 40.19 |
| 12:09 ET | 300 | 40.24 |
| 12:12 ET | 400 | 40.22 |
| 12:14 ET | 212 | 40.2618 |
| 12:16 ET | 200 | 40.23 |
| 12:18 ET | 100 | 40.25 |
| 12:20 ET | 728 | 40.27 |
May 7, 2024
DJ Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 7:05AM ET on Tuesday May 07, 2024 by Dow Jones
7:05AM ET on Tuesday May 07, 2024 by Dow Jones
May 6, 2024
*DJ Celldex Therapeutics 1Q Loss/Shr 56c >CLDX, from 4:01PM ET on Monday May 06, 2024 by Dow Jones
4:01PM ET on Monday May 06, 2024 by Dow JonesCelldex Reports First Quarter 2024 Financial Results and Provides Corporate Update, from 4:01PM ET on Monday May 06, 2024 by Dow Jones
4:01PM ET on Monday May 06, 2024 by Dow Jones
Apr 17, 2024
DJ Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 10:46AM ET on Wednesday Apr 17, 2024 by Dow Jones
10:46AM ET on Wednesday Apr 17, 2024 by Dow JonesCelldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria, from 8:01AM ET on Wednesday Apr 17, 2024 by Dow Jones
8:01AM ET on Wednesday Apr 17, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Celldex Therapeutics Inc | 2.6B | -14.2x | --- |
MoonLake Immunotherapeutics | 2.6B | -55.9x | --- |
Janux Therapeutics Inc | 2.5B | -39.9x | --- |
Avidity Biosciences Inc | 2.5B | -8.9x | --- |
Merus NV | 2.6B | -16.6x | --- |
Dyne Therapeutics Inc | 2.3B | -6.7x | --- |
Company Information
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.
Contact Information
- Headquarters
- 53 Frontage Road, Suite 220HAMPTON, NJ, United States 08827
- Phone
- 908-200-7500
- Fax
- 302-655-5049
Executives
- Non-Executive Independent Chairman of the Board
- Karen Shoos
- President, Chief Executive Officer, Director
- Anthony Marucci
- Chief Financial Office, Senior Vice President, Secretary
- Sam Martin
- Executive Vice President, Chief Scientific Officer
- Tibor Keler
- Senior Vice President, General Counsel
- Freddy Jimenez
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.6B |
|---|---|
Revenue (TTM) | $6.1M |
Shares Outstanding | 65.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.52 |
EPS | $-2.84 |
Book Value | $7.68 |
P/E Ratio | -14.2x |
Price/Sales (TTM) | 433.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,679.17% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
